Pernix Therapeutics Holdings Inc. recently announced that it has been given positive feedback on its litigation in regards to the proposed generic version of Zohydro ER with Actavis Laboratories FL Inc. Read More »
The Biosimilars Council is hoping the Supreme Court will acknowledge the savings that biosimilar medications can offer to both patients and health systems. Read More »
The Office of Tissue Advancement Therapies, a branch of the Center for Biologics Evaluation and Research of the FDA, has progressed toward the acceptance of Ampio Pharmaceuticals' Ampion for a viable treatment option for severe osteoarthritis of the knee. Read More »
Bristol-Myers Squibb Co. and Pfizer Inc. will present eight of their abstracts at the American College of Cardiology's 66th Annual Scientific Session in Washington, D.C. March 17-19. Read More »
Merck, which is known as MSD outside the United States and Canada, and Pfizer Inc. recently announced the acceptance for review of three New Drug Applications by the U.S. Food and Drug Administration. Read More »
Amgen's results of its Repatha (evolocumab) cardiovascular outcomes trial will be released at the American College of Cardiology's 66th Annual Scientific Session, which is set to take place in Washington, D.C. March 17-19. Read More »
U.S. House Judiciary Chairman Bob Goodlatte (R-VA) has sent letters to the American Bar Association and every state bar association, urging the organizations to adopt requirements for warnings on trial lawyer advertisements that urge patients to discontinue the use of some medicines. Read More »
CVS Health has selected Epic as its new electronic health record system for its more specialized care program, CVS Specialty, which includes Accordant, a care management program available to individuals suffering from rare diseases. Read More »
Following a precautionary hold on the dosing of an FAAH inhibitor, Janssen has again begun its clinical research of this investigational medication in two Phase 2 studies. Read More »
Kim Nguyen, La Puenta, Calif., was recently named the recipient of the MD Labs/Rxight Scholarship Supporting Excellence in Pharmacy Students. Read More »
Sandoz, a Novartis division, has released data for its proposed biosimilar adalimumab (GP2017). Read More »
Takeda Pharmaceuticals U.S.A. Inc., a wholly owned subsidiary of Takeda Pharmaceutical Co. Ltd., is collaborating with Cognition Kit Ltd., a joint venture between Cambridge Cognition Holdings PLC and Ctrl Group Ltd., to pilot the use of an Apple Watch app that assesses cognitive function in patients with Major Depressive Disorder. Read More »
The National Association of Specialty Pharmacy named Sheila Arquette its new executive director. Read More »
Janssen Research & Development LLC (Janssen) recently announced findings from two Phase 3 studies reporting the efficacy and safety of guselkumab in the treatment of adults with moderate to severe plaque psoriasis. Read More »
California Pharmacists are now legally permitted to prescribe oral, transdermal and vaginal forms of hormonal contraceptives in certain situations. Read More »
In a recent February 2017 study, by Kidney International, found that Proton Pump Inhibitors (PPIs), may cause adverse effects on the human kidney. Read More »
The Food and Drug Administration has approved ALK's Biologics License Application for a sublingual immunotherapy tablet aimed at combating the negative effects caused by dust mite allergies. Read More »
The U.S. Food and Drug Administration has approved Noctivia nasal spray for adults who deal with nocturnal polyuria, a condition that causes overproduction of urine during the night. Read More »
BioPharm X Corp., a specialty pharmaceutical company focused on the dermatology market, recently shared early clinical and pre-clinical data for BPX-01 topical gel at the 2017 American Academy of Dermatology (AAD) Annual Meeting. Read More »
Immune Pharmaceuticals Inc. will broaden enrollment eligibility criteria for its 10-patient open label study of Bertilimumab in the treatment of Bullous Pemphigoid (BP) after data was compiled from three patients who completed treatment. Read More »
Alerts Sign-up
